Percutaneous endoscopic gastrostomy versus nasogastric tube feeding in post-stroke dysphagia: a meta-analysis study.

Top Stroke RehabilJan 7, 2026 (epub)
Clinical ResearchGastroenterologyNeurology

Gamal Youssef, Rania M Abdou, Khaled Bamakhrama et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis compared percutaneous endoscopic gastrostomy (PEG) with nasogastric tube (NGT) feeding in people with post-stroke dysphagia. It included 10 studies involving 1,416 participants and pooled outcomes using random-effects models. Compared with NGT, PEG was associated with lower pneumonia risk (RR 0.53; 95% CI 0.42-0.67; p < 0.001) and higher serum albumin (MD +4.56 g/L; 95% CI 1.25-7.87; p = 0.007). A lower pooled mortality risk was not confirmed in analyses restricted to randomised controlled trials.

Key findings

  • PEG was associated with lower pneumonia risk than NGT (RR 0.53; 95% CI 0.42-0.67; p < 0.001).
  • Serum albumin was higher with PEG (MD +4.56 g/L; 95% CI 1.25-7.87; p = 0.007).
  • Pooled mortality was lower with PEG (RR 0.70; 95% CI 0.50-0.98; p = 0.039), but this was not significant in RCT-only sensitivity analysis.
  • No significant differences were found in mid-arm circumference (p = 0.16) or length of stay (p = 0.34).

Why it matters

Feeding route may be relevant to pneumonia risk and nutritional status in post-stroke dysphagia. The findings suggest potential advantages of PEG for these outcomes, while the mortality result is less robust. Considering the balance of possible benefits, procedural risks, and individual factors is important when interpreting comparative feeding evidence.

What to keep in mind

The pooled mortality benefit was not significant in RCT-only sensitivity analysis, suggesting possible confounding. The authors call for further high-quality randomised controlled trials.

Source

Published in Top Stroke Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.